Product Details for ANDA 207124
DEFERASIROX (DEFERASIROX)
125MG
Marketing Status: Discontinued
250MG
Marketing Status: Discontinued
500MG
Marketing Status: Discontinued
125MG
Marketing Status: Discontinued
Active Ingredient: DEFERASIROX
Proprietary Name: DEFERASIROX
Dosage Form; Route of Administration: TABLET, FOR SUSPENSION; ORAL
Strength: 125MG
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A207124
Product Number: 001
Approval Date: Sep 23, 2022
Applicant Holder Full Name: TEVA PHARMACEUTICALS USA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
DEFERASIROX (DEFERASIROX)
Proprietary Name: DEFERASIROX
Dosage Form; Route of Administration: TABLET, FOR SUSPENSION; ORAL
Strength: 125MG
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A207124
Product Number: 001
Approval Date: Sep 23, 2022
Applicant Holder Full Name: TEVA PHARMACEUTICALS USA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
250MG
Marketing Status: Discontinued
Active Ingredient: DEFERASIROX
Proprietary Name: DEFERASIROX
Dosage Form; Route of Administration: TABLET, FOR SUSPENSION; ORAL
Strength: 250MG
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A207124
Product Number: 002
Approval Date: Sep 23, 2022
Applicant Holder Full Name: TEVA PHARMACEUTICALS USA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
DEFERASIROX (DEFERASIROX)
Proprietary Name: DEFERASIROX
Dosage Form; Route of Administration: TABLET, FOR SUSPENSION; ORAL
Strength: 250MG
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A207124
Product Number: 002
Approval Date: Sep 23, 2022
Applicant Holder Full Name: TEVA PHARMACEUTICALS USA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
500MG
Marketing Status: Discontinued
Active Ingredient: DEFERASIROX
Proprietary Name: DEFERASIROX
Dosage Form; Route of Administration: TABLET, FOR SUSPENSION; ORAL
Strength: 500MG
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A207124
Product Number: 003
Approval Date: Sep 23, 2022
Applicant Holder Full Name: TEVA PHARMACEUTICALS USA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
Proprietary Name: DEFERASIROX
Dosage Form; Route of Administration: TABLET, FOR SUSPENSION; ORAL
Strength: 500MG
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A207124
Product Number: 003
Approval Date: Sep 23, 2022
Applicant Holder Full Name: TEVA PHARMACEUTICALS USA INC
Marketing Status: Discontinued
Patent and Exclusivity Information